NCT04676477
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
- NCT04676477 ↗
- Active, not recruiting
- Daiichi Sankyo
- Focused
We haven't built an HCP commentary report on NCT04676477 (patritumab deruxtecan plus osimertinib; patritumab deruxtecan in locally advanced or metastatic EGFR-mutated NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04676477 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Open-Label Study of HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- HER3-DXd; HER3-DXd; Osimertinib; Osimertinib; HER3-DXd; HER3-DXd; Osimertinib
- Arms
- Dose Escalation: HER3-DXd + osimertinib · Experimental
- Second-line Dose Expansion: HER3-DXd + osimertinib (RCD) · Experimental
- Second-line Dose Expansion: HER3-DXd · Experimental
- First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 3; RCD) · Experimental
- First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4a) · Experimental
- First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4b) · Experimental
- Enrollment
- 246
- Primary outcomes
- Dose Escalation: Incidence of Dose-limiting Toxicities (DLT), Treatment-emergent Adverse Events (TEAE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI)
- Second-line Dose Expansion and First-line Dose Expansion: Objective Response Rate (ORR)
- Sponsor
- Daiichi Sankyo with AstraZeneca, Merck Sharp & Dohme LLC
- Start
- Jun 11, 2021
- Primary completion
- Jan 31, 2025
- Results posted
- No
- Registry record
- NCT04676477 · updated Oct 26, 2026